Ascletis Pharma Inc. has announced the commencement of a U.S. 13-week Phase IIa study involving participants with obesity or overweight, who have been dosed with the small molecule oral GLP-1 receptor agonist, ASC30. This investigational drug, designed for once-daily oral or once-monthly subcutaneous administration, demonstrated a placebo-adjusted mean body weight reduction of up to 6.5% from baseline after four weeks in a previous Phase Ib study. Topline data from the current Phase IIa study are expected to be presented in the fourth quarter of 2025. ASC30 is a new chemical entity with patent protection in the U.S. and globally until 2044.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.